tbuckley/cabot-search huggingface dataset:
Understanding Statistical Analysis in Randomized Trials: Tips and Tricks for Effective Review
Authors: Paolo Frumento, Alessia Gimelli
Journal:  (2025)

This review explores the critical role of statistical analysis in interpreting randomized controlled trials (RCTs), focusing on how these methods are used to evaluate the efficacy and safety of clinical interventions. RCTs are considered the gold standard in clinical research, yet their statistical complexity can make interpretation challenging. Understanding key statistical concepts, such as P-values, hazard ratios, and confidence intervals, is essential for distinguishing between statistical significance and clinical relevance. It is important to assess study design elements, including randomization methods, sample size calculations, and the handling of missing data, as these factors directly influence the validity of the findings. Additionally, the analysis plan-whether it follows an intention-to-treat approach or uses per-protocol analysis-can impact the interpretation of trial outcomes. Readers should also be aware of the distinction between pre-specified and post hoc analyses, as the latter can increase the risk of false positives. The appropriate interpretation of these elements ensures a balanced understanding of trial results, allowing clinicians and researchers to make evidence-based decisions.
HSR25-182: Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid Leukemia
Authors: Kathryn E. Flynn, Joan Clements, Karen DeMairo, Jennifer Hiller, David Wei, Nisha C. Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Kejal Jadhav, Gabriel Marquez, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guérin, Kelly Schoenbeck
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-182: Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid Leukemia" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-184: Association of Chimeric Antigen Receptor T-Cell Therapy and Social Vulnerability Index: A National View of Care Delivery Patterns
Authors: Christopher T. Su, Emisa Nategh, Alireza Boloori
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-184: Association of Chimeric Antigen Receptor T-Cell Therapy and Social Vulnerability Index: A National View of Care Delivery Patterns" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-204: Clinical Characteristics and Prognosis Associated With Low PSA in Patients With De Novo Metastatic Hormone Sensitive Prostate Cancer
Authors: Bohdan Baralo, Natasha N. Dziarnowski, Peter T. Daniels, Cody A. McIntire, Morgan M. Puglisi, John W. Melson, Asit K. Paul
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-204: Clinical Characteristics and Prognosis Associated With Low PSA in Patients With De Novo Metastatic Hormone Sensitive Prostate Cancer" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-205: Analyzing Demographic Trends and Cancer Resource Support Centers Affecting the Cancer Community in the Inland Empire
Authors: Bradley Ventayen, Francesca Johnson, Nicole Holder, Emmanuelle Morin, Jack Angeles, Erik Buetow, Francesca Bossone, Bonnie Blackman, Sachin Reddi, Jonathan Pai, Joél Arvizo-Zavala
Journal: Journal of the National Comprehensive Cancer Network (2025)
Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges
Authors: Fabio Luciani, Arman Safavi, Puneeth Guruprasad, Linhui Chen, Marco Ruella
Journal: Blood Cancer Discovery (2025)

Summary: Artificial intelligence could enhance chimeric antigen receptor T-cell therapy outcomes through optimization of all steps, from target identification, vector design, and manufacturing to personalized data-driven clinical decisions. In this report, we highlight steps toward unlocking this potential, including the need for standardized, comprehensive data repositories as a way for addressing barriers to artificial intelligence learning, such as data heterogeneity and patient privacy.
How I Became the “Goddess of Vitamin E”
Authors: Maret G. Traber
Journal: Annual Review of Nutrition (2025)

My scientific journey is not traditional; it begins with the career opportunities available for and expectations of young women during the outset of the women's liberation era and how life changed along the way. I've started my story when I was a child in the 1950s, daughter of a milkman and an immigrant fleeing the communists in her home country. My story reaches an apex when I became an internationally recognized vitamin E expert. Overall, I made transformative contributions to our understanding of α-tocopherol function in humans, and, using model systems, I have reported how its absence has a major impact on cellular metabolism. This is the story of my transformation. I have had some excellent mentors. I have a passion about learning why the body needs α-tocopherol. Certainly, when I started out, I had no expectations that I would become a world-renowned scientist, a term I now use to describe myself.
HSR25-207: Clinical Outcomes for Medicare Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample
Authors: Danielle C. Thor, Tony Elias, Ben Brik, Vineet Polineni
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-207: Clinical Outcomes for Medicare Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Dual αvβ6 and αvβ1 Inhibition Over 12 Weeks Reduces Active Type 1 Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial
Authors: Sydney B Montesi, Gregory P. Cosgrove, Scott M. Turner, Iris Y Zhou, Nikos Efthimiou, Antonia Susnjar, Ciprian Catana, Caroline Fromson, Annie Clark, Martin Decaris, Chris N. Barnes, Éric A Lefebvre, Peter Caravan
Journal: American Journal of Respiratory and Critical Care Medicine (2025)

Rationale: Idiopathic pulmonary fibrosis (IPF) is characterized by excessive deposition of type 1 collagen. 68Ga-CBP8, a type 1 collagen positron emission tomography (PET) probe, measures collagen accumulation and shows higher collagen deposition in patients with IPF. Bexotegrast (PLN-74809) is an oral, once-daily, dual-selective inhibitor of αvβ6 and αvβ1 integrins under late-stage evaluation for treatment of IPF. Objectives: Evaluate changes in type 1 collagen in the lungs of participants with IPF following treatment with bexotegrast. Methods: In this Phase 2 (NCT05621252), single-center, double-blind, placebo-controlled study, adults with IPF received bexotegrast 160mg or placebo for 12 weeks. Primary endpoint was the change in whole-lung standardized uptake value (SUV) of 68Ga-CBP8 PET. Changes in lung dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters, forced vital capacity (FVC), cough severity, and biomarkers of collagen synthesis and progressive disease were also assessed. Measurements and Main Results: Of 10 participants, 7 received bexotegrast and 3 placebo. At Week 12, mean change from baseline in top quartile of 68Ga-CBP8 whole-lung SUV was −1.2% with bexotegrast vs 6.6% with placebo; greatest mean changes were observed in subpleural lung regions in both groups (bexotegrast, −3.7%; placebo, 10.3%). DCE-MRI demonstrated numerically increased peak enhancement and faster contrast washout rate in bexotegrast-treated participants, suggesting improvements in lung microvasculature and decreased extravascular extracellular volume. Bexotegrast treatment resulted in numerical improvements in FVC, cough severity, and biomarker levels. Conclusions: The reduced uptake of 68Ga-CBP8 in the lungs of participants with IPF indicates an antifibrotic effect of bexotegrast, suggesting the potential for favorable lung remodeling.
HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials
Authors: Ramaditya Srinivasmurthy, Hazem Aboaid, Abbas Hussain, Riccesha Hattin, Savannah Schauer, Tal Schlesinger, Rory Twells, Karl Aharonian, Ryan Parto, Rodd Rahmani, Chalette Lambert-Swainston, Daniel Thomas Jones, Kyaw Zin Thein
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Practical Anemia Bundle and Hemoglobin Recovery in Critical Illness
Authors: Matthew A. Warner, Matthew L. Johnson, Andrew C. Hanson, Emma Fortune, Gerald W. Flaby, Phillip J. Schulte, Valerie M. Hazelton, Ronald S. Go, W. Brian Beam, Jonathan E. Charnin, Brenda K. Anderson, Brad Karon, Andrea L. Cheville, Ognjen Gajic, Daryl J. Kor
Journal: JAMA Network Open (2025)

Importance Anemia is a common complication of surgery and acute illness that is associated with adverse clinical outcomes. The role of anemia prevention and treatment strategies in this setting remains unclear. Objective To evaluate the effect of a multifaceted anemia management bundle vs standard care on posthospitalization hemoglobin recovery and multidimensional functional outcomes in survivors of acute illness. Design, Setting, and Participants This parallel group randomized clinical trial, known as the Practical Anemia Bundle for Sustained Blood Recovery, was conducted at postsurgical and medical intensive care units at a large US medical center. Critically ill patients (aged ≥18 years) with moderate to severe anemia (hemoglobin concentration &amp;amp;lt;10 g/dL) were enrolled between March 2022 and November 2023. Participants were randomly assigned 1:1 to the intervention or standard care group. Intention-to-treat analyses were performed between July 2024 and January 2025. Intervention The intervention bundle was delivered throughout the duration of hospitalization and included optimized phlebotomy practices, clinical decision support, and pharmacological anemia treatment with intravenous iron. Main Outcomes and Measures The primary outcome was the mean difference in hemoglobin concentration at 1 month after hospital discharge. Results A total of 100 patients (median [IQR] age, 68 [61-72] years; 57 men [57.0%]; 65 [65.0%] with postsurgical admission to the intensive care unit) were enrolled during acute illness. Forty-nine patients (49.0%) were assigned to receive the intervention, and 51 (51.0%) were assigned to receive standard care. Hemoglobin concentration at 1 month after discharge was greater in patients receiving the intervention vs standard care (median [IQR], 12.2 [11.8-13.0] g/dL vs 11.5 [10.2-12.6] g/dL; adjusted mean difference, 0.69 [95% CI, 0.13-1.20] g/dL; P = .02). Conclusions and Relevance This randomized clinical trial found that a multifaceted anemia prevention and treatment bundle was feasible, was well tolerated, and improved posthospitalization hemoglobin concentrations up to 3 months in critically ill adults. These findings can inform the design of future trials. Trial Registration ClinicalTrials.gov Identifier: NCT05167734
Targeted Clostridioides difficile infection antimicrobial stewardship ward rounds - it takes a team
Authors: Sadhbh Gash, Niamh Weir, Miriam Russell, Lisa Rogers, Mairead Skally, Caoimhe Finn, Sinead O'Donnell, Karina O'Connell, Helene McDermott, Binu Dinesh, Fidelma Fitzpatrick, Karen Burns, Ciara O'Connor
Journal: Journal of Infection (2025)
HSR25-153: Patient Preferences and Willingness to Accept Trade-Offs for a Favorable Treatment Response Among Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Authors: Pratyusha Vadagam, Lisa Dwyer Orr, Julie Vanderpoel, Margaret Yung, Kathleen L. Deering, Victoria Kulbokas
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-153: Patient Preferences and Willingness to Accept Trade-Offs for a Favorable Treatment Response Among Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-166: Linking COVID-Related Distress and Mental Health Service Utilization Among Allogeneic Hematopoietic Stem Cell Transplant Patients
Authors: Halle R. Smith, Marilyn Horta, Skye O. Dougan, Sierra J. Washington, Helen C. Yates, Joseph Pidala, Maija Reblin, Heather Jim, Steven K. Sutton, Christine Vinci
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-166: Linking COVID-Related Distress and Mental Health Service Utilization Among Allogeneic Hematopoietic Stem Cell Transplant Patients" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-175: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Venous Thromboembolism (VTE) and Immune-Related Adverse Events (iRAEs) in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Immunochemotherapy
Authors: Daniel Thomas Jones, Hazem Aboaid, Ramaditya Srinivasmurthy, Kevin Nguyen, Jason Ta, Benjamin Tzer-Ming Chuang, Rishi Kumar Nanda, Yin Mon Myat, Kyaw Zin Thein
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-175: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Venous Thromboembolism (VTE) and Immune-Related Adverse Events (iRAEs) in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Immunochemotherapy" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Epidemiology of Shigella species and serotypes in children: a retrospective substudy of the MAL-ED observational birth cohort study
Authors: Elizabeth T Rogawski McQuade, Jie Liu, Mustafa Mahfuz, Alexandre Havt, Tintu Varghese, Jasmin Shrestha, Furqan Kabir, Pablo Peñataro Yori, Amidou Samie, Queen Saidi, Adil Kalam, Fatima Aziz, Sahrish Muneer, Rashidul Haque, Aldo A M Lima, Maheswari Kalaivanan, Sanjaya Shrestha, Najeeha Talat Iqbal, Zulfiqar Bhutta, Margaret N Kosek, Pascal Bessong, Estomih Mduma, James A Platts-Mills, Eric R Houpt
Journal: The Lancet Microbe (2025)
HSR25-160: Evaluating Patient Characteristics, Treatment Patterns, Clinical Outcomes, and Health Care Resource Use in Pemigatinib-Treated Cholangiocarcinoma (CCA) Patients: A Focus on Cancer of Unknown Primary
Authors: Sumit Verma, Sunyoung Lee, Mike Blecker, Alejandro Hughes, Nicole M. Engel-Nitz, Shreekant Parasuraman, Milind Javle
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-160: Evaluating Patient Characteristics, Treatment Patterns, Clinical Outcomes, and Health Care Resource Use in Pemigatinib-Treated Cholangiocarcinoma (CCA) Patients: A Focus on Cancer of Unknown Primary" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-155: Racial Disparities in Palliative Care (PC) Access Among Patients With Malignant Brain Tumors (MBT): A Retrospective Analysis Using the National Inpatient Sample (2014–2020)
Authors: Nehemias Antonio Guevara Rodriguez, Noemy Coreas, Esmirna Perez, Binay Kumar Panjiyar, Patxis Taveras, Lina Toledo Franco, Asha Ricciuti
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-155: Racial Disparities in Palliative Care (PC) Access Among Patients With Malignant Brain Tumors (MBT): A Retrospective Analysis Using the National Inpatient Sample (2014–2020)" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-161: Potential Factors Impacting Adherence With National Comprehensive Cancer Network Radiation Therapy Guidelines for Early-Stage Breast Cancer.
Authors: Rosaleen Duggan Bloom, Wen Hsin Chen, Jane Nelson Bolin
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-161: Potential Factors Impacting Adherence With National Comprehensive Cancer Network Radiation Therapy Guidelines for Early-Stage Breast Cancer." published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-090: MiR-31 as a Predictive Biomarker of Cetuximab Efficacy in Metastatic Colorectal Cancer Patients
Authors: Thanmai Reddy Thugu, Muskan Jain, Neeharika John Madhavaram, Neha Singh, Sonali Dash, Ahmad Alhomaid, Sai Gautham Kanagala, Laxman Yashwant Byreddi, Akhil Jain, Rupak Desai
Journal: Journal of the National Comprehensive Cancer Network (2025)
HSR25-170: Investigating Socioeconomic and Racial Disparities in Pathologic Response and Survival Outcomes in Triple-Negative Breast Cancer Post-Neoadjuvant Chemotherapy: Insights From the National Cancer Database
Authors: Zunairah Shah, Malak Alharbi, Mengyu Fang, Han Yu, Shipra Gandhi
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-170: Investigating Socioeconomic and Racial Disparities in Pathologic Response and Survival Outcomes in Triple-Negative Breast Cancer Post-Neoadjuvant Chemotherapy: Insights From the National Cancer Database" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-178: Initial Clinical Presentation (ICP) and Pre-Diagnostic Journey During 18 Months Before a First Non-Small Cell Lung Cancer (NSCLC) Diagnosis: US Retrospective Cohort Study
Authors: Melissa L. Santorelli, Molly Scannell Bryan, Ashwini Arunachalam, Xiaohan Hu, Ashleigh E. McBratney, Connor Sweetnam, Lori Boice, Kristiana Wilkinson, Ronda G. Broome, Anna B. Berry, Monica A. Izano
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-178: Initial Clinical Presentation (ICP) and Pre-Diagnostic Journey During 18 Months Before a First Non-Small Cell Lung Cancer (NSCLC) Diagnosis: US Retrospective Cohort Study" published on 28 Mar 2025 by National Comprehensive Cancer Network.
EPR25-124: Epidemiology of Giant Cell Glioblastoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis
Authors: Hassan Ali, Shammas Bajwa, Satya Durugu, Sivaguha Yadunath Prabhakaran, Hafiz Muhammad Ajmal Saleem, Elizaveta Bodrova, Jaison Lawrence Alexander Santhi, Rajesh Thirumaran
Journal: Journal of the National Comprehensive Cancer Network (2025)
HSR25-149: Racial Disparities in Non-Small Cell Lung Cancer Survival Outcomes: A Systemic Review and Meta-Analysis
Authors: Chalothorn Wannaphut, Ben Ponvilawan, Chanakarn Kanitthamniyom, Narathorn Kulthamrongsri, Vitchapong Prasitsumrit, Phuuwadith Wattanachayakul, Manasawee Tanariyakul, Sakditad Saowapa
Journal: Journal of the National Comprehensive Cancer Network (2025)
HSR25-176: Efficacy of Immunochemotherapy in Primary Advanced or Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials (RCTs)
Authors: Ramaditya Srinivasmurthy, Hazem Aboaid, Daniel Thomas Jones, Kevin Nguyen, Jason Ta, Benjamin Tzer-Ming Chuang, Rishi Kumar Nanda, Yin Mon Myat, Kyaw Zin Thein
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-176: Efficacy of Immunochemotherapy in Primary Advanced or Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials (RCTs)" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-144: Clinical Outcomes for Leukemia Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample
Authors: Danielle C. Thor, Tony Elias, Vineet Polineni, Ben Brik
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-144: Clinical Outcomes for Leukemia Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-203: Cost-Effectiveness Evaluation of Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments Among Medicare Patients With Chronic Lymphocytic Leukemia (CLL) in First-Line (1L) and Relapsed/Refractory (R/R) Settings
Authors: Samuel Crawford, Huimin Li, Bhavini Srivastava, Pam Martin, James Gahn, Shaffee Bacchus, Olga Ryan, Monika Salkar
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-203: Cost-Effectiveness Evaluation of Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments Among Medicare Patients With Chronic Lymphocytic Leukemia (CLL) in First-Line (1L) and Relapsed/Refractory (R/R) Settings" published on 28 Mar 2025 by National Comprehensive Cancer Network.
TIP25-246: Evaluating the Effect of a Mindfulness-Based Intervention on Metabolic and Immunological Biomarkers of Stress Among Caregivers of Allogeneic Hematopoietic Stem Cell Transplant Recipients: Trial in Progress
Authors: Ranjita Poudel, Fnu Amisha, Sierra Washington, Halle R. Smith, Skye O. Dougan, Min-Jeong Yang, Marilyn Horta, Farhad Khimani, Christine Vinci
Journal: Journal of the National Comprehensive Cancer Network (2025)

"TIP25-246: Evaluating the Effect of a Mindfulness-Based Intervention on Metabolic and Immunological Biomarkers of Stress Among Caregivers of Allogeneic Hematopoietic Stem Cell Transplant Recipients: Trial in Progress" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-142: Assessment of Community Oncology Palliative and Supportive Care Program in Improving Patient’s Quality of Life: A Patients Perspective
Authors: MaryAnn Fragola
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-142: Assessment of Community Oncology Palliative and Supportive Care Program in Improving Patient's Quality of Life: A Patients Perspective" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-202: Epidemiology and Outcomes of Ventricular Arrhythmias in Patients With Hypercalcemia of Malignancy: A Population-Based Study
Authors: Adamsegd Isac Gebremedhen, Mamdouh Souleymane, Ibrahim Shanti, Yonas Fetle, Samson Teka, Stephen Roy, Donald R Lynch
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-202: Epidemiology and Outcomes of Ventricular Arrhythmias in Patients With Hypercalcemia of Malignancy: A Population-Based Study" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Categorizing Concentration Confidence: A Framework for Reporting Concentration Measures from Mass Spectrometry-based Assays
Authors: Lauren M. Petrick, David Achaintre, Amith Maroli, Julio Landero, Priyanthi S. Dessanayake, Susan L. Teitelbaum, Mary S. Wolff, Manish Arora, Robert O. Wright, Syam S. Andra
Journal: Environmental Health Perspectives (2025)

Innovation in mass spectrometry-based methods to both quantify and perform discovery has blurred the lines between targeted and untargeted assays of biospecimens. Continuous data—concentrations or intensity values generated from both methods—can be used in statistical analysis to determine associations with health outcomes, but concentration values are needed to compare measurements from one study to another, to inform policy making decisions, and to develop clinically relevant thresholds. As a single solution for discovery and quantitation, new hybrid-type assays derive concentration values for chemicals or metabolites, but with varying degrees of uncertainty that may be greater than traditional quantitative assays. There is no current single standard to guide reporting bioassay concentrations or their uncertainty in concentration values from hybrid assays. Even when measures are robust, obtained with high scientific rigor, and provide valuable data towards risk assessment, unknown uncertainty can lead to bias in interpretation of reported data or omission of reported data that doesn't meet the strict criteria for absolute quantitation.
QIM25-227: Evaluating Dosimetric Differences in Head and Neck Cancer Treatment: A RapidArc Approach With Flattening Filter-Free vs. Filtered Beams
Authors: Kailash Kumar Mittal, Atul Mishra, Sumanta Manna, Neha Yadav, Sharad Singh
Journal: Journal of the National Comprehensive Cancer Network (2025)

"QIM25-227: Evaluating Dosimetric Differences in Head and Neck Cancer Treatment: A RapidArc Approach With Flattening Filter-Free vs. Filtered Beams" published on 28 Mar 2025 by National Comprehensive Cancer Network.